Coronavirus vaccine players  are on watch this morning ahead of Phase 1 trial results of AstraZeneca’s  (NYSE:AZN)  COVID-19 vaccine developed with the University of Oxford, which will be published in  The Lancet.

Reports last week suggested the journal will release positive news – the vaccine is believed to be in one of the most advanced stages of clinical trials (involving 9,000 patients in South Africa and Brazil).

Overnight, the U.K. also secured early access to 90 Million doses of vaccines in development by drugmakers including Pfizer  (NYSE:PFE), BioNTech  (NASDAQ:BNTX)  and Valneva  (OTC:INRLF), while GlaxoSmithKline  (NYSE:GSK)  inked a deal with CureVac to develop RNA-based vaccines and antibodies.

In just six months since the coronavirus outbreak, 140 vaccine candidates are in the pre-clinical trial stage and 23 have entered the clinical evaluation stage, according to the World Health Organization.

Also a potential coronavirus vaccine developed by Oxford University in the U.K with pharmaceutical giant AstraZeneca  has produced a promising immune response early-stage human trial.

Photo Credit :  Morning Brew Unplash